Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Micturition Reflex01:26

The Micturition Reflex

531
Urination, or micturition involves the coordination of the bladder's detrusor muscle and two sphincters to ensure controlled bladder emptying.
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating...
531
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

156
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
156
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

151
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
151
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

189
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
189
Urinary Bladder01:23

Urinary Bladder

520
The urinary bladder is a hollow, muscular sac that temporarily stores urine before it is expelled from the body. It can hold approximately 600 mL of urine prior to micturition. The bladder is retroperitoneal and located behind the pubic symphysis in the pelvic floor.
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
520
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

477
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
477

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sacral Neuromodulation in the Management of Refractory Pediatric Lower Urinary Tract Dysfunction.

Neurourology and urodynamics·2026
Same author

Spinal anesthesia with caudal catheter in pediatric urologic surgery: an alternative to general anesthesia.

Frontiers in pediatrics·2025
Same author

The development of surgical ability during pediatric urology fellowship and its evolution in the early years of practice.

Journal of pediatric urology·2024
Same author

An Uncommon Case of Sinonasal Adenoid Cystic Carcinoma Metastatic to the Kidney Treated with Metastasectomy.

Journal of kidney cancer and VHL·2024
Same author

Sacral nerve stimulation leads to long-term improvement in fecal incontinence and quality of life for children with functional and organic defecation disorders.

Neurogastroenterology and motility·2024
Same author

Editorial Comment.

The Journal of urology·2023

Related Experiment Video

Updated: Jun 18, 2025

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
10:19

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

19.3K

Third-Line Therapeutic Interventions for Non-Neurogenic Bladder Dysfunction in Children.

Alyssa M Lombardo1, Seth A Alpert2,3

  • 1Department of Urology, The Ohio State University Wexner Medical Center, Columbus, OH, U.S.

Current Urology Reports
|August 2, 2024
PubMed
Summary
This summary is machine-generated.

This review covers third-line treatments for pediatric non-neurogenic bladder dysfunction, including Botulinum toxin A (BoTNA), Posterior Tibial Nerve Stimulation (PTNS), and Sacral Neuromodulation (SNM), discussing their efficacy and considerations.

Keywords:
Bladder disorderBotulinumOveractive bladderPosterior tibial nerveSacral plexus

More Related Videos

Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

2.0K
Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
10:26

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

26.3K

Related Experiment Videos

Last Updated: Jun 18, 2025

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
10:19

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

19.3K
Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

2.0K
Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
10:26

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

26.3K

Area of Science:

  • Pediatric Urology
  • Neurology
  • Pharmacology

Background:

  • Pediatric non-neurogenic bladder dysfunction requires effective third-line treatment options.
  • Emerging therapies and long-term data are crucial for managing these conditions.

Purpose of the Study:

  • To review the considerations and efficacy of third-line treatments for pediatric non-neurogenic bladder dysfunction.
  • To evaluate Botulinum toxin A (BoTNA), Posterior Tibial Nerve Stimulation (PTNS), and Sacral Neuromodulation (SNM).

Main Methods:

  • Literature review of current evidence on third-line therapies.
  • Analysis of efficacy, safety, and practical considerations for each treatment modality.

Main Results:

  • Beta-3-agonists may offer a new step before third-line treatments.
  • Long-term data on pediatric Sacral Neuromodulation (SNM) efficacy and complications are becoming available.
  • Botulinum toxin A (BoTNA) effectively reduces detrusor contractility but has limitations.
  • Posterior Tibial Nerve Stimulation (PTNS) shows promise but is time-intensive.
  • SNM has a high success rate across various lower urinary tract dysfunctions (LUTD) but requires consideration of cumulative exposures.

Conclusions:

  • Third-line treatments like BoTNA, PTNS, and SNM offer valuable options for pediatric non-neurogenic bladder dysfunction.
  • Careful patient selection and consideration of treatment-specific factors are essential for optimal outcomes.
  • Ongoing research and long-term data collection are vital for refining treatment strategies.